This work model AD progression as a deviation from aging using longitudinal amyloid PET and a self-supervised trajectory-learning framework and reveals a shared early path that bifurcated into an aging branch and an AD-related branch.
Abstract
Aging is the greatest risk factor for Alzheimer’s disease (AD), yet how and when AD-related pathological progression diverges from aging remains poorly understood. This distinction is particularly difficult at early stages, when clinically and biomarker-defined populations contain individuals following fundamentally different trajectories. Here, we model AD progression as a deviation from aging using longitudinal amyloid PET and a self-supervised trajectory-learning framework. In ADNI, the learned trajectory revealed a shared early path that bifurcated into an aging branch and an AD-related branch. The two branches showed distinct profiles in amyloid burden, cognitive decline, risk of progression to AD dementia, and genetic risk. Unseen participants from the independent NACC cohort were projected onto the trajectory without retraining, further reproducing key branch-specific biological and genetic patterns. Together, the bifurcating trajectory provides a biologically grounded framework for resolving early-stage heterogeneity and enabling risk stratification beyond binary amyloid status.
The findings broaden the understanding that AD dementia is shaped jointly by pathological burden and cognitive resilience, and argue for therapeutic trial and prevention strategies that strengthen resilience alongside reducing pathology.
Routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.
R. R. Butler, M. Brown, A. Weber et al.· medRxiv· 1 citation
The study reveals marked variability among individuals who are otherwise all defined as cognitively normal, and provides a data-driven stratification framework for enriching disease-modifying and preventive trials by identifying cognitively normal individuals at high risk for future cognitive decline.
Alzheimer’s disease is widely conceptualized as a biological continuum initiated by amyloid-β (Aβ) accumulation, followed by tau aggregation and neurodegeneration. Although the ATN framework is commonly used to define disease stages, its static biomarker categories may not fully capture the dynamic pathological transit...
Evidence supports a shift from a linear amyloid model to a multidimensional framework and offers promise for early detection, risk stratification, and personalized multi-target therapies in AD.
C. D. Souza, Shiva Murthy Nanjundappa, N. Murali· International Journal of Bas...· 0 citations
A practical multi-axis framework comprising clinical phenotype, AD biological context (AD pathology plus co-pathologies and molecular modifiers), network topography (regional patterns) and tempo (rate of clinical and biomarker progression) is proposed to reduce diagnostic mismatches, make cohorts more comparable and su...
L. Grinberg, M. Murray· Nature Reviews Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.